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In a paper by Yadav and colleagues, a novel pathway linking the central nervous system effects of leptin on
bone mass and energy expenditure to serotonin signaling in brainstem circuits is described. The data from
those studies strengthen the tenet that skeletal remodeling is intimately connected to central regulation of
metabolism.
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PreviewsIn a recent issue of Cell, Yadav et al.
achieve a tour de forcemapping networks
in the central nervous system (CNS) that
link bone turnover to energy expenditure
through serotonergic connections in the
brainstem (Yadav et al., 2009). In doing
so, the authors propose a new paradigm
for the mechanism of action of leptin in
the central regulation of bone mass.
However, to place these novel observa-
tions in context and to fully appreciate
the sea change that has occurred in our
understanding of skeletal physiology, it
is worth remembering that a decade ago,
bone was not on the metabolic map, nor
was it thought to be influenced by the
CNS. Rather, most investigations focused
on endocrine, paracrine, and autocrine
regulators of the bone remodeling unit.
That changed when Ducy et al. made
the seminal observation that ob/ob mice
had very high bone mass despite the
absence of gonadal steroids (Ducy et al.,
2000). This finding flew in the face of the
well-established paradigm that sex hor-
mones are the most important regulators
of bone remodeling. Subsequent studies
validated the original hypothesis that the
CNS and sympathetic outflow signifi-
cantly influenced skeletal turnover. Work
by the Karsenty group and others detailed
the cellular and molecular targets of b2
adrenergic activation and the role leptin
played in mediating these downstream
events (Elefteriou et al., 2005; Fu et al.,
2005). More recently, serotonin has
emerged as a potential endocrine medi-
ator of bone turnover in mice and as
a neurotransmitter that, when altered by
drugs or genetic manipulation, could indi-
rectly impact bone strength and mass
(Yadav et al., 2008).
The current paper by Yadav et al. link-
ing leptin to serotonin signaling strength-ens the tenet that the skeleton is regulated
by the CNS and is an essential compo-
nent of manymetabolic processes (Yadav
et al., 2009) (Figure 1). Their approach is
worth summarizing. First, the authors es-
tablished that the brainstem was the prin-
cipal site of synthesis of Tph2, an enzyme
essential for the generation of serotonin in
the CNS. Next, they demonstrated that
global deletion of Tph2 resulted in an
osteoporotic phenotype that was pro-
nounced with both the Tph1 and Tph2
genes deleted. Yadav et al. rescued the
low bone mass phenotype by crossing
Tph2/ animals with mice that were
either heterozygous or homozygous for
deletion of the b2 adrenergic receptor,
thereby establishing that sympathetic
outflow was the final common pathway
for brainstem-derived serotonin (BDS)
actions on bone. At that point, a more
difficult challenge faced the investigators,
i.e., determining howBDSwas connected
to the hypothalamus. Through elegant
anatomical mapping experiments, the
authors describe a heretofore unknown
connection between axons from Tph2-
expressing neurons that project into the
hypothalamus with binding of serotonin to
the hydroxytryptamine receptor, Htr2c,
in the ventromedial nucleus. Proof of its
functional importance came from global
deletion of Htr2c. These mice had ex-
tremely low bone mass, increased Ucp1
expression, and high adrenergic tone but
were rescued by genetically restoring
Htr2c. The authors then connected leptin
to serotonin by noting that the leptin-defi-
cient ob/ob mouse had 10-fold higher
Tph2 expression and significantly more
serotonin in the brainstem than wild-type
mice. They also showed that leptin could
directly inhibit serotonergic neuronal
activity. Lastly, by deleting the leptinCell Metabolismreceptor (ObRb) in the brainstem only,
these mice recapitulated the ob/ob skel-
etal phenotype. Remarkably, these ani-
mals also exhibited a decrease in Mc4r
and Pomc transcripts that were identical
to that observed in the ob/ob mouse.
Thus, several lines of evidence suggest
that leptin suppresses brainstem seroto-
nergic neurons that in turn modulate
bone turnover as well as energy expendi-
ture and appetite through distinct neural
connections to the hypothalamus.
Notwithstanding these findings, several
provocative questions persist. First, why
does leptin make a right turn to the brain-
stem, and why does it regulate serotonin?
The hypothalamus controls numerous
metabolic processes, expresses the
ObRb, and is the center of energy regula-
tion. Yet teleologically, the brainstem
evolved much earlier than the neocortex
and is morphologically similar across a
wide range of species. The brainstem
also carries ascending and descending
neurons for autonomic functions and
plays a major role in modulating move-
ment and balance. Importantly, 5-hy-
droxytryptamine (serotonin) and its recep-
tors are highly conserved across all
multicellular organisms (Zarse and Ris-
tow, 2008). In C. elegans, serotonin is an
important chemosensor that modulates
signaling to distinct subsets of neurons
in order to translate molecular plasticity
to behavioral outcomes (Chao et al.,
2004). Moreover, in vertebrates, serotonin
entrains the master clock in the supra-
chiasmatic nucleus of the hypothalamus,
integrating environmental signals into
circadian rhythms (Cuesta et al., 2009).
Hence, it is not surprising that seroto-
nergic activity in the brainstem would be
an essential component of a neuronal
network for fine-tuning skeletal responses10, October 7, 2009 ª2009 Elsevier Inc. 243
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Previewsto environmental signaling. Second, does
the leptin-serotonin paradigm fit the prin-
cipal function of the bone remodeling unit
for maintenance of calcium balance and
bone strength? Bone-forming osteoblasts
and bone-resorbing osteoclasts require
energy to complete a cycle during which
the skeleton is remodeled. In adult hu-
mans, 10% of the skeleton is remodeled
each year, and this process must be
coupled to both fuel intake and energy
consumption. In the scenario proposed
by Yadav and colleagues, serotonin sup-
presses sympathetic outflow from the
hypothalamus, lowering oxygen con-
sumption (i.e., via reduced UCP1 and
less adrenergic tone) and enhancing
appetite during peak bone formation. On
the other hand, during states of energy
surplus, serotonergic signaling is sup-
pressed by leptin, leading to a reduction
in caloric intake, increased energy con-
sumption, and cessation of bone forma-
tion with greater bone resorption. Inter-
estingly, if this paradigm is correct, then
an increase in BDS could serve as a
counter to enhanced secretion of gut-
derived serotonin, which works in an
endocrine manner to inhibit bone forma-
tion and is triggered by food in the intes-
tine (Figure 1) (Rosen, 2009). In these
circumstances, the bone remodeling unit
should beworking at peak efficiency while
sensing environmental determinants such
as fuel status and energy consumption.
The final question relates to the pressing
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Figure 1. Leptin’s Regulation of Bone Mass and the Relationship of the Skeleton to
Metabolic Processes
The skeleton is integrated within a larger metabolic network that is regulated by the CNS. The hypothal-
amus contains nuclei that control appetite (ARC, arcuate nucleus), sympathetic outflow and energy
expenditure (VMH, ventromedial hypothalamus), and the master oscillator for the circadian clock (SCN,
suprachiasmatic nucleus). The sympathetic nervous system inhibits bone formation, enhances bone
resorption, and stimulates lipolysis in fat cells. According to Yadav et al., leptin acts to inhibit serotonergic
neurons in the brainstem, which are destined for the hypothalamus to regulate VMH output, appetite
centers in the ARC, and the master oscillator in the SCN. Leptin may also act directly on these centers
(dotted lines) as an anorexigenic peptide, while insulin and serotonin act as orexigenic stimuli. The
bone-specific protein osteocalcin in turn modulates insulin secretion and sensitivity in adipocytes. Circu-
lating 5-HT, serotonin, is produced principally in the gut in response to food and can inhibit osteoblast-
mediated bone formation, acting as a negative feedback to the orexigenic stimulus from serotonergic
neurons in the hypothalamus.244 Cell Metabolism 10, October 7, 2009 ª2009 Elsevier Inc.clinical issue of how widely used antide-
pressive and antipsychotic medications
affect body composition. There are no
randomized trials, but observational and
cohort studies suggest that selective
serotonin reuptake inhibitors (SSRIs)
cause bone loss and weight gain and
may lead to increased fracture risk
(Rosen, 2009). Although the Yadav paper
was not designed to address this ques-
tion, a reduction in serotonergic signaling
(i.e., loss of Tph2 activity) produces an
osteopenic phenotype that resembles
animal studies in which the 5-hydroxy-
tryptamine transporter (5HTT) is deleted
(Warden et al., 2005). More investigations
will be required to determine if dynamic
changes in either local or circulating sero-
tonin affect skeletal acquisition and adi-
pose distribution. Still, the mapping and
genetic studies of Yadav et al. provide
a fresh look at the power of the CNS and
its role in regulating skeletal metabolism.
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